Month: September 2025

Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease

Lindis Blood Care Announces Publication of Final Results from Pivotal REMOVE Study with CATUVAB(R) in the Journal of Clinical Anesthesia

Primary endpoint met, demonstrating depletion of EpCAM (epithelial cell adhesion molecule)-positive cancer cells from intraoperatively salvaged blood (p<0,0001)All safety endpoints,...

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical...

Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care

VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")is pleased to...

error: Content is protected !!